Exicure (XCUR) Change in Account Payables (2016 - 2026)
Exicure's (XCUR) quarterly Change in Account Payables came in at $755000.0 in Q1 2026, up 276.81% YoY from $200363.6 in Q1 2025, and up 86.88% on a QoQ basis from $404000.0 in Q4 2025.
Exicure (XCUR) Change in Account Payables (2016 - 2026) Analysis & Trends
Exicure (XCUR) has 11 years of Change in Account Payables data on file, last reported at $755000.0 in Q1 2026.
- Quarterly Change in Account Payables rose 276.81% year-over-year to $755000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (up 266.95% YoY) and the FY2025 annual result came in at $177000.0, up 191.71% from the prior year.
- Change in Account Payables advanced to $755000.0 in Q1 2026, from $404000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $766000.0 in Q4 2023 to a low of -$1.5 million in Q1 2022.
- A 5-year average of -$61352.9 and a median of -$109000.0 in 2023 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2022 — Change in Account Payables sank 414.49% — and 2025, when it surged 404.17%.
- Tracing XCUR's Change in Account Payables over 5 years: stood at -$559000.0 in 2022, then soared by 237.03% to $766000.0 in 2023, then plunged by 86.95% to $100000.0 in 2024, then soared by 304.0% to $404000.0 in 2025, then surged by 86.88% to $755000.0 in 2026.
- The last three Change in Account Payables figures came in at $755000.0 (Q1 2026), $404000.0 (Q4 2025), and -$530000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Exicure | 7.27 Mn | 7.27 Mn | - | -260,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 755,000.00 |
| Mar 31, 2026 | 755,000.00 |
| Dec 31, 2025 | 404,000.00 |
| Dec 31, 2025 | 404,000.00 |
| Sep 30, 2025 | -530,000.00 |
| Sep 30, 2025 | -530,000.00 |
| Jun 30, 2025 | 730,000.00 |
| Jun 30, 2025 | 730,000.00 |
| Mar 31, 2025 | -427,000.00 |
| Mar 31, 2025 | -427,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | -247,000.00 |
| Sep 30, 2024 | -247,000.00 |
| Jun 30, 2024 | -240,000.00 |
| Jun 30, 2024 | -240,000.00 |
| Mar 31, 2024 | 194,000.00 |
| Mar 31, 2024 | 194,000.00 |
| Dec 31, 2023 | 766,000.00 |
| Dec 31, 2023 | 766,000.00 |